Business
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the presentation of data from its Phase 3 HOPE-3 clinical trial of Deramiocel in Duchenne muscular dystrophy (DMD) at the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Illinois. The data were presented by Dr. Aravindhan Veerapandiyan, Associate Professor and Director of th
About this update from Capricor Therapeutics, Inc.
[{"type":"image","alt":"Capricor Therapeutics","displaySize":"","headline":null,"caption":"Capricor Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zxF_h93Haluc.n40vlL.sQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MA--/https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7","width":300,"height":107}},"lazy":false},{"type":"text","content":"SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the presentation of data from its Phase 3 HOPE-3 clinical trial of Deramiocel in Duchenne muscular dystrophy (DMD) at the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Illinois. The data were presented by Dr. Aravindhan Veerapandiyan, Associate Professor and Director of the Comprehensive Neuromuscular Program at Arkansas Children's Hospital, during the Late-Breaking Science 2 session on Tuesday, April 21, 2026.","length":645,"tagName":"p"},{"type":"text","content":"AAN Presentation Highlights","length":27,"tagName":"p"},{"type":"text","content":""No therapeutic has ever delivered a statistically and clinically meaningful difference in the upper limb functional primary endpoint of Performance of the Upper Limb (PUL v2.0)," said Dr. Aravindhan Veerapandiyan, Associate Professor and Director of the Comprehensive Neuromuscular Program at Arkansas Children's Hospital. "These findings were further supported by an alternative measure of upper limb function, specifically video recordings of tasks performed at home (the Duchenne Video Assessment, or DVA), which showed meaningful slowing of disease progression in the ability to self-feed, a function central to patient independence. These data reinforce the potential of Deramiocel to make a meaningful difference in the lives of those living with Duchenne."","length":788,"tagName":"p"},{"type":"text","content":""Bringing these results to AAN reflects the significant momentum behind Deramiocel and our deep commitment to the Duchenne community," said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. "The...